News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
79,876 Results
Type
Article (5739)
Company Profile (38)
Press Release (74099)
Section
Business (21974)
Career Advice (257)
Deals (2794)
Drug Delivery (3)
Drug Development (13529)
Employer Resources (9)
FDA (3785)
Job Trends (2651)
News (42183)
Policy (3714)
Tag
Academia (527)
Allergies (47)
Alliances (6600)
Alzheimer's disease (188)
Approvals (3789)
Artificial intelligence (35)
Bankruptcy (13)
Best Places to Work (2546)
Biotechnology (32)
Breast cancer (22)
Cancer (176)
Career advice (221)
Cell therapy (31)
Clinical research (10788)
Collaboration (81)
Compensation (19)
COVID-19 (411)
C-suite (19)
Data (197)
Diabetes (16)
Diagnostics (976)
Drug discovery (16)
Earnings (5347)
Events (10945)
Executive appointments (44)
FDA (3880)
Featured Employer (14)
Funding (45)
Gene therapy (21)
GLP-1 (57)
Government (576)
Healthcare (1967)
Infectious disease (422)
Inflammatory bowel disease (25)
Interviews (31)
IPO (1295)
Job creations (223)
Job search strategy (204)
Layoffs (20)
Legal (360)
Lung cancer (24)
Manufacturing (18)
Medical device (436)
Medtech (436)
Mergers & acquisitions (1523)
Metabolic disorders (45)
Multiple sclerosis (14)
Neuroscience (253)
NextGen Class of 2024 (613)
Non-profit (436)
Northern California (245)
Obesity (24)
Opinion (24)
Parkinson's disease (23)
Peanut (39)
People (8628)
Phase I (2755)
Phase II (3838)
Phase III (4611)
Pipeline (39)
Postmarket research (737)
Preclinical (1370)
Press Release (38)
Radiopharmaceuticals (28)
Rare diseases (28)
Real estate (458)
Regulatory (2998)
Research institute (548)
Resumes & cover letters (27)
Southern California (216)
Startups (577)
United States (1871)
Vaccines (84)
Weight loss (14)
Date
Last 7 days (142)
Last 30 days (493)
Last 365 days (6324)
2024 (5106)
2023 (6949)
2022 (8370)
2021 (8940)
2020 (7250)
2019 (5603)
2018 (4104)
2017 (4431)
2016 (4128)
2015 (4542)
2014 (3009)
2013 (2279)
2012 (2311)
2011 (2519)
2010 (1995)
Location
Africa (104)
Asia (4451)
Australia (638)
California (522)
Canada (80)
Connecticut (18)
Delaware (20)
Europe (11586)
Florida (26)
Illinois (32)
Indiana (29)
Japan (18)
Maryland (84)
Massachusetts (395)
Minnesota (14)
New Jersey (257)
New York (140)
North Carolina (84)
Northern California (245)
Ohio (27)
Pennsylvania (70)
South America (131)
Southern California (216)
Texas (28)
Utah (15)
Washington State (63)
79,876 Results for "reaction biology".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Reaction Biology Launches Innovative Offering Within Its Kinase Testing Platform and Presents New Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
Reaction Biology (“Reaction” or the “Company”), an industry-leading provider of drug discovery and development services, today announced that it will feature its recently launched HotSpot™ ATP-Max KinomeScreen at the American Association for Cancer Research (AACR) Annual Meeting 2024, held April 7-10, 2024, in San Diego, California.
April 3, 2024
·
6 min read
Approvals
ARS Pharma Gets FDA Green Light for First Nasal Spray for Severe Allergic Reactions
ARS Pharma’s neffy on Friday became the first FDA-approved nasal spray to address severe allergic reactions, including those that might lead to life-threatening anaphylaxis.
August 12, 2024
·
2 min read
·
Tristan Manalac
Biotech Bay
Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology
Cytokinetics, Incorporated announced that the Company will host the muscle biology-focused Contemporary Landscapes in Muscle Biology Research Symposium , May 17th, 2024 at the Mission Bay Conference Center in San Francisco.
May 17, 2024
·
5 min read
Policy
ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)
ARS Pharmaceuticals, Inc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion on the application for marketing authorization for EURneffy® and recommended related market authorization in the European Union for the emergency treatment of allergic reactions.
June 28, 2024
·
6 min read
Pharm Country
New York’s Only Outpatient Program for Reducing Allergic Reactions to Cancer Treatments Hits New Care Milestone
Approximately 10% of people diagnosed with cancer experience hypersensitivity reactions to certain therapies—which range from a mild skin rash to anaphylaxis —even when they were pretreated with antihistamines and steroids.
May 20, 2024
·
4 min read
Pharm Country
Reaction Biology to Present Data at AACR 2023 Showcasing Expansive Capabilities in Immuno-Oncology Drug Discovery and Development
Reaction Biology (“Reaction” or the “Company”) today announced that eleven abstracts highlighting data from the Company’s expanding suite of research offerings will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, held April 14-19, 2023, in Orlando, Florida.
April 12, 2023
·
5 min read
Press Releases
BlinkRx is Now Offering neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
October 7, 2024
·
2 min read
Drug Development
EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
August 26, 2024
·
6 min read
FDA
FDA Approves First Medication to Help Reduce Allergic Reactions to Multiple Foods After Accidental Exposure
The U.S. Food and Drug Administration approved Xolair injection for immunoglobulin E-mediated food allergy in certain adults and children 1 year or older for the reduction of allergic reactions, including reducing the risk of anaphylaxis, that may occur with accidental exposure to one or more foods.
February 16, 2024
·
5 min read
Drug Development
Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT® (amivantamab-vmjw)
September 10, 2024
·
31 min read
1 of 7,988
Next